Holen Sie sich die Stockscreener-App
28.75
1.45%
0.41
Handel nachbörslich:
28.86
0.11
+0.38%
Assembly Biosciences Inc Aktie (ASMB) Neueste Nachrichten
Assembly Biosciences Completes Significant Equity Offering Financing - TipRanks
Assembly Biosciences closes $115 million stock offering - Investing.com
Assembly Bio raises $115M for viral and liver drug clinical work - Stock Titan
Assembly Biosciences Surges 6.9% as Buyers Defend Key Support Level (ASMB)BPI Bull Correction - Newser
Assembly Biosciences prices $100M equity offering - MSN
Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday - Sahm
Key facts: Assembly Biosciences Offers; ABI-6250 Expanded to PBC/PSC - TradingView
Assembly Biosciences (ASMB) Expands Clinical Focus on Liver Dise - GuruFocus
Assembly Biosciences (ASMB) Prices $100M Offering to Support Cli - GuruFocus
Assembly Biosciences (NASDAQ: ASMB) launches stock and pre-funded warrant offering - Stock Titan
Assembly Biosciences prices $100 million stock offering at $26.50 - Investing.com UK
Assembly Biosciences Expands ABI-6250 Clinical Development to Target Cholestatic Liver Diseases Including PBC and PSC - Minichart
Assembly Biosciences expands ABI-6250 development to liver diseases By Investing.com - Investing.com Nigeria
Assembly Biosciences prices $100 million stock offering at $26.50 By Investing.com - Investing.com South Africa
Assembly Biosciences prices $100 million offering - The Pharma Letter
Assembly Biosciences Shares Up Amid Expansion of ABI-6250 Drug Development - Moomoo
Assembly Biosciences stock surges on PBC and PSC expansion plan By Investing.com - Investing.com Nigeria
Assembly Biosciences stock surges on PBC and PSC expansion plan - Investing.com
Assembly Biosciences Expands ABI-6250 Liver Disease Program - TipRanks
Assembly Biosciences Prices $100 Million Offering - Moomoo
Assembly Bio (NASDAQ: ASMB) plans Phase 2 ABI-6250 trials in HDV, PBC and PSC - Stock Titan
Assembly Biosciences Plans Phase 2 Study of ABI-6250 in Cholestatic Liver Diseases PBC and PSC to Begin in Q1 2027 - Quiver Quantitative
Assembly Biosciences expands ABI-6250 development to liver diseases - Investing.com
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases - The Manila Times
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants - marketscreener.com
Biotech Assembly Bio prices $100M sale to fund viral, liver drug work - Stock Titan
Experimental liver drug ABI-6250 heads to Phase 2 tests in PBC and PSC - Stock Titan
Crude Oil Edges Higher; US Consumer Sentiment Falls In May - Sahm
Trading Systems Reacting to (ASMB) Volatility - Stock Traders Daily
Assembly Biosciences, Inc.Common Stock (ASMB) Stock Price, News, Quote & History - FinancialContent
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference - Yahoo Finance
Assembly Biosciences Shares Caution As Healthcare Growth Expectations Fade - Kalkine Media
These Analysts Just Made A Huge Downgrade To Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Forecasts - simplywall.st
Assembly Biosciences to present HDV drug data at EASL congress - Investing.com
Assembly Biosciences to present HDV drug data at EASL congress By Investing.com - Investing.com Australia
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 - The Manila Times
Assembly Biosciences to Present Topline Clinical Data on ABI-6250, a Novel Oral Hepatitis D Virus Entry Inhibitor, at EASL Congress 2026 - Quiver Quantitative
Oral hepatitis D entry inhibitor brings Phase 1a data to Barcelona - Stock Titan
MarketsMedicine Hat News - FinancialContent
Paradigm entities and Dr. Asefaw report holdings in Assembly Biosciences (ASMB) - Stock Titan
Analysts Have Lowered Expectations For Assembly Biosciences, Inc. (NASDAQ:ASMB) After Its Latest Results - simplywall.st
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference - Weekly Voice
Biotech Assembly Bio to speak at BofA 2026 Global Health Care Conference - Stock Titan
We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely - Yahoo Finance
Guggenheim Maintains Assembly Biosciences(ASMB.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Assembly Biosciences 1Q Loss/Shr 54c >ASMB - Moomoo
How Assembly Bio (ASMB) benefits from the shifts in its industry (-1.37%) 2026-05-08SuperTrend - Newser
Assembly Biosciences (ASMB) reports Q1 loss, misses revenue estimates - MSN
Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates - Yahoo! Finance Canada
Assembly Biosciences (NASDAQ: ASMB) posts Q1 loss, holds $226.6M cash - Stock Titan
Assembly Biosciences (NASDAQ: ASMB) Q1 2026 results with $8.2M revenue - Stock Titan
Assembly Biosciences Q1 revenue falls, net loss widens - TradingView
Assembly Biosciences: Q1 Earnings Snapshot - marketscreener.com
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):